Samantha Bosis

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Platelet Rich Plasma

Immune Response

Top Venues

Human vaccines & immunotherapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Federico M Torres, Ignacio Salamanca de la Cueva, Michael Horn, Soeren Westerholt, Samantha Bosis, Nadia Meyer, Brigitte Cheuvart, Navpreet Virk, Rupert W Jakes, Maurine Duchenne, Peter Van den Steen
Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule. Human vaccines & immunotherapeutics 20 (1) (2024)
Federico M Torres, Ignacio Salamanca de la Cueva, Michael Horn, Soeren Westerholt, Samantha Bosis, Nadia Meyer, Brigitte Cheuvart, Navpreet Virk, Rupert W Jakes, Maurine Duchenne, Peter Van den Steen
Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule. Human vaccines & immunotherapeutics 20 (1) (2024)
Federico M Torres, Ignacio Salamanca de la Cueva, Michael Horn, Soeren Westerholt, Samantha Bosis, Nadia Meyer, Brigitte Cheuvart, Navpreet Virk, Rupert W Jakes, Maurine Duchenne, Peter Van den Steen
Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule. Human vaccines & immunotherapeutics 20 (1) (2024)
Federico M Torres, Ignacio Salamanca de la Cueva, Michael Horn, Soeren Westerholt, Samantha Bosis, Nadia Meyer, Brigitte Cheuvart, Navpreet Virk, Rupert W Jakes, Maurine Duchenne, Peter Van den Steen
Disparate kinetics in immune response of two different Haemophilus influenzae type b conjugate vaccines: Immunogenicity and safety observations from a randomized controlled phase IV study in healthy infants and toddlers using a 2+1 schedule. Human vaccines & immunotherapeutics 20 (1) (2024)